+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Periodic Fever Syndrome - Global Strategic Business Report

  • PDF Icon

    Report

  • 390 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106483
The global market for Periodic Fever Syndrome was estimated at US$618.8 Million in 2024 and is projected to reach US$745.6 Million by 2030, growing at a CAGR of 3.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Periodic Fever Syndrome market.

Global Periodic Fever Syndrome Market - Key Trends & Drivers Summarized

What Characterizes Periodic Fever Syndromes and Why Are They Often Misdiagnosed?

Periodic fever syndromes are a group of rare, autoinflammatory disorders characterized by recurrent episodes of fever and systemic inflammation without infection. These syndromes, such as PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis), Familial Mediterranean Fever (FMF), and TRAPS (TNF Receptor-Associated Periodic Syndrome), typically present in childhood and are linked to mutations in genes regulating the innate immune system.

Misdiagnosis is common due to symptom overlap with infections or autoimmune diseases. As awareness grows, more accurate clinical recognition and genetic testing are helping clinicians differentiate between infectious, autoimmune, and autoinflammatory causes of recurrent fevers. Although rare, these syndromes have significant impacts on quality of life, school attendance, and caregiver burden, prompting early diagnosis and long-term care planning.

How Is Diagnosis and Treatment Progressing with Advancements in Genetics and Immunology?

Genetic testing plays a central role in confirming hereditary periodic fever syndromes. Targeted next-generation sequencing (NGS) panels and exome sequencing are increasingly used in tertiary centers to identify mutations in MEFV, TNFRSF1A, and other related genes. Biomarker studies, particularly interleukin-1 (IL-1) pathway involvement, are guiding treatment decisions.

Treatment approaches vary by subtype. Colchicine is the standard therapy for FMF, while corticosteroids are often used in PFAPA. Biologic therapies targeting IL-1 (e.g., anakinra, canakinumab) and TNF-alpha are increasingly used in refractory or genetically confirmed syndromes. Disease-modifying strategies aim to reduce attack frequency and severity while minimizing long-term organ damage.

Where Is the Clinical Focus Shifting and Which Stakeholders Are Investing in Research?

Academic hospitals and pediatric rheumatology centers are primary settings for diagnosis and care. In North America and Europe, national rare disease registries and collaborative research networks are supporting deeper clinical and genetic characterization of periodic fever syndromes. In the Middle East and Mediterranean regions, where FMF is more prevalent, regional awareness and screening programs are being strengthened.

Pharmaceutical companies are investing in biologic therapies for autoinflammatory diseases, targeting rare syndromes with orphan drug designations. Genetic diagnostics firms are developing panels focused on pediatric autoinflammatory conditions, enabling earlier intervention. Patient advocacy organizations are working to increase recognition among clinicians and policy makers to improve access to specialist care and biologic therapies.

Growth in the Periodic Fever Syndrome market is driven by several factors

Growth in the periodic fever syndrome market is driven by factors such as increased recognition of autoinflammatory diseases, expanding access to genetic testing, and greater availability of targeted biologic therapies. Improved diagnostic algorithms, along with broader application of sequencing in pediatric medicine, are leading to earlier and more accurate identification of rare febrile syndromes.

Regulatory incentives for orphan drugs and expanded indications for IL-1 and TNF inhibitors are encouraging biopharma investment. Development of long-acting biologics and increased clinician awareness through rare disease education programs are further supporting market growth. As patient registries and cross-border research initiatives mature, periodic fever syndromes are receiving more structured clinical attention, driving innovation and market expansion in this specialized segment.

Scope Of Study:

The report analyzes the Periodic Fever Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Syndrome (HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome, Other Syndromes); Treatment (Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy, Statins Treatment, Other Treatments); End-Use (Hospitals End-Use, Retail Pharmacy End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the HyperimmunoGlobulinemia D syndrome segment, which is expected to reach US$346.5 Million by 2030 with a CAGR of a 4.0%. The Familial Mediterranean Fever Syndrome segment is also set to grow at 1.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $168.6 Million in 2024, and China, forecasted to grow at an impressive 6.1% CAGR to reach $148.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Periodic Fever Syndrome Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Periodic Fever Syndrome Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Periodic Fever Syndrome Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Inc., AB2 Bio Ltd, Amgen Inc., AstraZeneca plc, BioCryst Pharmaceuticals and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 48 companies featured in this Periodic Fever Syndrome market report include:

  • AbbVie Inc.
  • AB2 Bio Ltd
  • Amgen Inc.
  • AstraZeneca plc
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Horizon Therapeutics (Amgen)
  • InnoCare Pharma
  • Kiniksa Pharmaceuticals
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sobi (Swedish Orphan Biovitrum)
  • Takeda Pharmaceutical Company

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Periodic Fever Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Diagnosis Rates of Autoinflammatory Disorders Spurs Demand for Targeted Treatments for Periodic Fever Syndromes
  • Increased Genetic Testing Capabilities Strengthen Early Identification and Classification of Hereditary Fever Disorders
  • Growth in Pediatric Rheumatology Awareness Throws the Spotlight on Underdiagnosed Recurrent Fever Conditions
  • Expansion of Biologic Therapies and IL-1 Inhibitors Supports Clinical Management of Resistant Cases
  • OEM Investment in Orphan Drug Development Encourages Pipeline Growth for Rare Autoinflammatory Indications
  • Advancements in Next-Generation Sequencing (NGS) Enhance Detection of Mutations in MEFV, TNFRSF1A, and Related Genes
  • Global Expansion of Autoinflammatory Disease Registries Improves Clinical Understanding and Therapeutic Strategy Development
  • Rising Adoption of Precision Medicine Supports Individualized Treatment Pathways in PFAPA and CAPS Patients
  • Pediatric Specialist Training and Referral Networks Promote Timely Diagnosis and Long-Term Disease Monitoring
  • Integration of Telehealth and Remote Monitoring Tools Facilitates Management of Flare Frequency and Response Tracking
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Periodic Fever Syndrome Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Periodic Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for HyperimmunoGlobulinemia D syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for HyperimmunoGlobulinemia D syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for HyperimmunoGlobulinemia D syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Familial Mediterranean Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Familial Mediterranean Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Familial Mediterranean Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for TNF Receptor-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for TNF Receptor-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for TNF Receptor-Associated Periodic Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Cryopyrin-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Cryopyrin-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Cryopyrin-Associated Periodic Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Syndromes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Syndromes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Syndromes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oral Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oral Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Oral Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Anti-TNF Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Anti-TNF Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Anti-TNF Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Statins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Statins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Statins Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacy End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Retail Pharmacy End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Retail Pharmacy End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • AB2 Bio Ltd
  • Amgen Inc.
  • AstraZeneca plc
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Horizon Therapeutics (Amgen)
  • InnoCare Pharma
  • Kiniksa Pharmaceuticals
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sobi (Swedish Orphan Biovitrum)
  • Takeda Pharmaceutical Company

Table Information